发明授权
- 专利标题： Drug targeting
- 专利标题（中）： 药物靶向
-
申请号： US09367261申请日： 1998-02-13
-
公开(公告)号： US07829555B1公开(公告)日： 2010-11-09
- 发明人: David Blake , Declan Naughton , Ged Adams , Ian Stratford , Christopher Morris , Mohammed Jaffar , Matthew Naylor
- 申请人： David Blake , Declan Naughton , Ged Adams , Margaret Adams, legal representative , Ian Stratford , Christopher Morris , Mohammed Jaffar , Matthew Naylor
- 申请人地址： GB Manchester
- 专利权人： The University of Manchester
- 当前专利权人： The University of Manchester
- 当前专利权人地址： GB Manchester
- 代理机构： Nixon & Vanderhye P.C.
- 优先权： GB9703002.7 19970213; GB9712090.1 19970610
- 国际申请： PCT/GB98/00461 WO 19980213
- 国际公布： WO98/35701 WO 19980820
- 主分类号： A61K31/573
- IPC分类号： A61K31/573 ; C07J5/00
摘要：
The invention provides a method of targeting a drug to areas of hypoxic and/or ischemic tissue within the body in which the desired drug species is linked to a non-cytotoxic bioreductive carrier. Also provided by the invention are novel bioreductive conjugates comprising a non-cytotoxic bioreductive moiety with linked-thereto at least one therapeutic agent. The compounds of the invention are particularly suitable for the treatment of rheumatoid arthritis and other arthritic conditions, diabetes, atherosclerosis, stroke, sepsis, Alzheimer's disease and other neurological disorders, cancer, kidney disease, digestive diseases, liver disease, chronic periodontitis or ischemia following tissue transplantation.
信息查询
